Raymond GV. Leukodystrophy: basic and clinical. Adv Neurobiol. 2017;15:365–82.
Deon M, Marchetti DP, Donida B, Wajner M, Vargas C. Oxidative stress in patients with X-linked adrenoleukodystrophy. Cell Mol Neurobiol. 2015;36:497–512.
PubMed Article CAS Google Scholar
Ohashi T. Gene therapy for lysosomal storage diseases and peroxisomal diseases. J Hum Genet. 2018;64:139–43.
Powers JM, Pei Z, Heinzer AK, Deering R, Moser AB, Moser HW, et al. Adreno-leukodystrophy: oxidative stress of mice and men. J Neuropathol Exp Neurol. 2005;64:1067–79.
CAS PubMed Article Google Scholar
Jia MR, Wu WZ, Li CM, Cai XH, Zhang L, Yan F, et al. Clinical characteristics and phenotype distribution in 10 chinese patients with X-linked adrenoleukodystrophy. Exp Ther Med. 2019;18:1945–52.
CAS PubMed PubMed Central Google Scholar
Kemp S, Berger J, Aubourg P. X-linked adrenoleukodystrophy: Clinical, metabolic, genetic and pathophysiological aspects. Biochim Biophys Acta. 2012;1822:1465–74.
CAS PubMed Article Google Scholar
Sassa T, Wakashima T, Ohno Y, Kihara A. Lorenzo’s oil inhibits ELOVL1 and lowers the level of sphingomyelin with a saturated very long-chain fatty acid. J Lipid Res. 2014;55:524–30.
CAS PubMed PubMed Central Article Google Scholar
Ciftciler R, Goker H, Buyukasik Y, Topcu M, Gevher N, Demiroglu H. The experience of allogeneic hematopoietic stem cell transplantation in a patient with X-linked adrenoleukodystrophy. Transfus Apher Sci. 2020;59:102583.
Mallack EJ, Turk B, Yan H, Eichler FS. The landscape of hematopoietic stem cell transplant and gene therapy for X-linked adrenoleukodystrophy. Curr Treat Options Neurol. 2019;21:61.
Thwaite R, Pagès G, Chillón M, Bosch A. AAVrh.10 immunogenicity in mice and humans. Relevance of antibody cross-reactivity in human gene therapy. Gene Ther. 2014;22:196–201.
PubMed Article CAS Google Scholar
Zhao L, Gottesdiener AJ, Parmar M, Li M, Kaminsky SM, Chiuchiolo MJ, et al. Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer’s disease mouse models. Neurobiol Aging. 2016;44:159–72.
CAS PubMed Article Google Scholar
Tardieu M, Zérah M, Gougeon M-L, Ausseil J, de Bournonville S, Husson B, et al. Intracerebral gene therapy in children with mucopolysaccharidosis type IIIb syndrome: an uncontrolled phase 1/2 clinical trial. Lancet Neurol. 2017;16:712–20.
CAS PubMed Article Google Scholar
Russell KN, Mitchell NL, Anderson NG, Bunt CR, Wellby MP, Melzer TR, et al. Computed tomography provides enhanced techniques for longitudinal monitoring of progressive intracranial volume loss associated with regional neurodegeneration in ovine neuronal ceroid lipofuscinoses. Brain Behav. 2018;8:e01096.
PubMed PubMed Central Article Google Scholar
Chien Y-H, Lee N-C, Tseng S-H, Tai C-H, Muramatsu S-I, Byrne BJ, et al. Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1/2 trial. Lancet Child Adoles Health. 2017;1:265–73.
Naso MF, Tomkowicz B, Perry WL 3rd, Strohl WR. Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs. 2017;31:317–34.
CAS PubMed PubMed Central Article Google Scholar
Chang L-J, Urlacher V, Iwakuma T, Cui Y, Zucali J. Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system. Gene Ther. 1999;6:715–28.
CAS PubMed Article Google Scholar
Chang L-J, Gay EE. The molecular genetics of lentiviral vectors - current and future perspectives. Curr Gene Ther. 2001;1:237–51.
CAS PubMed Article Google Scholar
Engelen M, Kemp S, Poll-The BT. X-linked adrenoleukodystrophy: Pathogenesis and treatment. Curr Neurol Neurosci Rep. 2014;14:486.
PubMed Article CAS Google Scholar
Eichler F, Duncan C, Musolino PL, Orchard PJ, De Oliveira S, Thrasher AJ, et al. Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy. N Engl J Med. 2017;377:1630–8.
CAS PubMed PubMed Central Article Google Scholar
Nathalie Cartier SH-B-A. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science. 2009;326:818–23.
PubMed Article CAS Google Scholar
Palfi S, Gurruchaga JM, Ralph GS, Lepetit H, Lavisse S, Buttery PC, et al. Long-term safety and tolerability of prosavin, a lentiviral vector-based gene therapy for Parkinson’s disease: a dose escalation, open-label, phase 1/2 trial. Lancet. 2014;383:1138–46.
CAS PubMed Article Google Scholar
Meneghini V, Lattanzi A, Tiradani L, Bravo G, Morena F, Sanvito F, et al. Pervasive supply of therapeutic lysosomal enzymes in the CNS of normal and Krabbe-affected non-human primates by intracerebral lentiviral gene therapy. EMBO Mol Med. 2016;8:489–510.
CAS PubMed PubMed Central Article Google Scholar
Chang L-J, Liu X, He J. Lentiviral siRNAs targeting multiple highly conserved RNA sequences of human immunodeficiency virus type 1. Gene Ther. 2005;12:1133–44.
CAS PubMed Article Google Scholar
Gong J, Chung T-H, Zheng J, Zheng H, Chang L-J. Transduction of modified factor VIII gene improves lentiviral gene therapy efficacy for hemophilia A. J Biol Chem. 2021;297:101397.
CAS PubMed PubMed Central Article Google Scholar
Vowells SJ, Sekhsaria S, Malech HL, Shalit M, Fleisher TA. Flow cytometric analysis of the granulocyte respiratory burst: a comparison study of fluorescent probes. J Immunol Meth. 1995;178:89–97.
Pujol A, Hindelang C, Callizot N, Bartsch U, Schachner M, Mandel JL. Late onset neurological phenotype of the X-ALD gene inactivation in mice: a mouse model for adrenomyeloneuropathy. Hum Mol Genet. 2002;11:499–505.
CAS PubMed Article Google Scholar
Lu JF, Lawler AM, Watkins PA, Powers JM, Moser AB, Moser HW, et al. A mouse model for X-linked adrenoleukodystrophy. Proc Natl Acad Sci USA. 1997;94:9366–71.
CAS PubMed PubMed Central Article Google Scholar
Kobayashi T, Shinnoh N, Kondo A, Yamada T. Adrenoleukodystrophy protein-deficient mice represent abnormality of very long chain fatty acid metabolism. Bioch and Biophys Res Comm. 1997;232:5.
Turk BR, Theda C, Fatemi A, Moser AB. X-linked adrenoleukodystrophy: pathology, pathophysiology, diagnostic testing, newborn screening and therapies. Int J Dev Neurosci. 2020;80:52–72.
PubMed PubMed Central Article Google Scholar
Igarashi M, Schaumburg HH, Powers J, Kishmoto Y, Kolodny E, Suzuki K. Fatty acid abnormality in adrenoleukodystrophy. J Neurochem. 1976;26:851–60.
CAS PubMed Article Google Scholar
Vargas CR, Wajner M, Sirtori LR, Goulart L, Chiochetta M, Coelho D, et al. Evidence that oxidative stress is increased in patients with X-linked adrenoleukodystrophy. Biochim Biophys Acta. 2004;1688:26–32.
CAS PubMed Article Google Scholar
Uto T, Contreras MA, Gilg AG, Singh I. Oxidative imbalance in nonstimulated X-adrenoleukodystrophy-derived lymphoblasts. Dev Neurosci. 2008;30:410–8.
CAS PubMed Article Google Scholar
Di Biase A, Di Benedetto R, Fiorentini C, Travaglione S, Salvati S, Attorri L, et al. Free radical release in C6 glial cells enriched in hexacosanoic acid: Implication for X-linked adrenoleukodystrophy pathogenesis. Neurochem Int. 2004;44:215–21.
PubMed Article CAS Google Scholar
Hocquemiller M, Giersch L, Audrain M, Parker S, Cartier N. Adeno-associated virus-based gene therapy for CNS diseases. Hum Gene Ther. 2016;27:478–96.
CAS PubMed PubMed Central Article Google Scholar
Chen Y, Zheng S, Tecedor L, Davidson BL. Overcoming limitations inherent in sulfamidase to improve mucopolysaccharidosis IIIa gene therapy. Mol Ther. 2018;26:1118–26.
CAS PubMed PubMed Central Article Google Scholar
Fu H, Meadows AS, Ware T, Mohney RP, McCarty DM. Near-complete correction of profound metabolomic impairments corresponding to functional benefit in MPS IIIb mice after IV rAAV9-hNAGLU gene delivery. Mol Ther. 2017;25:792–802.
CAS PubMed PubMed Central Article Google Scholar
Tardieu M, Zerah M, Husson B, de Bournonville S, Deiva K, Adamsbaum C, et al. Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIa disease: results of a phase I/II trial. Hum Gene Ther. 2014;25:506–16.
CAS PubMed Article Google Scholar
Liu W, Zhao L, Blackman B, Parmar M, Wong MY, Woo T, et al. Vectored intracerebral immunization with the anti-Tau monoclonal antibody PHF1 markedly reduces Tau pathology in mutant Tau transgenic mice. J Neurosci. 2016;36:12425–35.
留言 (0)